Tresiba (Insulin Degludec) in Geriatric Patients (65+): Transitioning to Adult Care

What Makes Insulin Degludec Different for Older Adults

Insulin degludec forms soluble multi-hexamer chains at the injection site, producing a depot that releases insulin slowly and evenly over more than 42 hours. That flat pharmacokinetic profile directly reduces day-to-day glucose variability, a property that matters more in a 72-year-old than in a 35-year-old because older adults have blunted counter-regulatory hormone responses to hypoglycemia. [1]

Pharmacokinetics at a Glance

Degludec's half-life of roughly 25 hours is nearly double that of glargine U-100 (12 hours) and significantly longer than glargine U-300 (19 hours). The coefficient of variation for the glucose-lowering effect of degludec is approximately 20%, compared with 82% for NPH insulin, based on euglycemic clamp data. [2] Lower within-day variability means fewer unexpected glucose troughs, which is especially relevant for patients who skip meals or have irregular schedules, both common in the geriatric population.

Why Flat Pharmacokinetics Reduce Fall Risk

Nocturnal hypoglycemia is the leading driver of fall-related fractures in insulin-treated older adults. The BEGIN Basal-Bolus Type 2 trial (N=992) reported a 25% lower rate of confirmed nocturnal hypoglycemia with degludec compared with glargine U-100 (relative risk 0.75, 95% CI 0.60 to 0.94, P<0.05) at similar HbA1c reductions. [3] Falls are the leading cause of injury death in adults aged 65 and older, making that nocturnal hypoglycemia reduction clinically meaningful beyond glucose numbers alone.

Flexible Dosing Window

Degludec can be injected at any time of day, with the interval between injections ranging from 8 to 40 hours without loss of glycemic control, based on a treat-to-target study in 88 subjects. [4] For older adults whose caregivers rotate shifts or who have variable mealtimes, this flexibility removes one of the most common adherence barriers associated with rigid injection windows.

ADA and AACE Guideline Recommendations for Geriatric Insulin Users

The American Diabetes Association 2024 Standards of Care (Section 13: Older Adults) categorize older patients into three health tiers: healthy, complex/intermediate, and very complex/poor health. Each tier carries a distinct HbA1c target. [5]

ADA 2024 Glycemic Targets by Geriatric Health Tier

• Healthy (few chronic conditions, intact cognition): HbA1c <7.0 to 7.5%
• Complex/Intermediate (multiple chronic conditions or mild cognitive impairment): HbA1c <8.0%
• Very complex/poor health (end-stage conditions, moderate-to-severe dementia): HbA1c <8.5%, or avoidance of symptomatic hyperglycemia rather than strict targets

The ADA explicitly states: "Overtreatment of diabetes is common in older adults and should be avoided. Recommended targets should reflect patient goals, health status, and life expectancy." [5]

AACE Position on Basal Insulin Choice in Seniors

The American Association of Clinical Endocrinology 2022 Diabetes Algorithm recommends preferring degludec or glargine U-300 over glargine U-100 in patients at elevated hypoglycemia risk, a category that includes most adults over 65 who are on insulin. [6] AACE places hypoglycemia avoidance above marginal HbA1c optimization in frail older patients, a stance backed by evidence that severe hypoglycemia is independently associated with accelerated cognitive decline and cardiovascular events in this age group. [7]

How to Transition Geriatric Patients to Tresiba

Switching an older adult to degludec requires a structured protocol that accounts for the risk of both over- and under-insulinization during the conversion window.

Step 1: Assess Before You Switch

Before any basal insulin transition in a patient aged 65 or older, confirm:

1. Current eGFR. Insulin clearance slows as eGFR falls below 45 mL/min/1.73 m2, increasing hypoglycemia risk. [8]
2. Cognitive and functional status. Patients with moderate dementia may not reliably self-inject or recognize hypoglycemia symptoms.
3. Current HbA1c and fasting glucose. A patient already at HbA1c 7.0% on 40 units of glargine is at higher conversion risk than one at 9.5%.
4. Renal and hepatic function panels.
5. Current hypoglycemia frequency. Any history of severe hypoglycemia (requiring third-party assistance) in the past six months warrants an even more conservative conversion.

Step 2: Calculate the Starting Dose

The FDA-approved prescribing information for Tresiba recommends converting unit-for-unit from glargine or detemir for most adults. For geriatric patients specifically, clinical practice guidelines and the FDA label both note that older adults may be more sensitive to insulin and that a dose reduction should be considered. [9]

A 20% dose reduction from the prior total daily basal insulin dose is the standard practice adopted by most academic endocrinology centers transitioning older adults. For example:

• Prior dose: 30 units glargine U-100 once daily
• 20% reduction: 30 x 0.80 = 24 units degludec as the starting dose
• Round to the nearest 2 units on the FlexTouch pen dial

If the patient was on NPH twice daily, add both doses, then apply the 20% reduction to the total, and give degludec once daily.

Step 3: Titration Protocol

Because degludec reaches steady state in 2 to 3 days (3 to 4 days in some older adults with slower subcutaneous absorption), titration adjustments should not occur more often than every 3 to 4 days. A fasting glucose-guided titration schedule used in the BEGIN trials increased the dose by 2 units every 3 days when fasting glucose exceeded 90 mg/dL, targeting 70 to 90 mg/dL. [3]

For geriatric patients, a more conservative titration target of 80 to 130 mg/dL fasting is appropriate, aligned with the ADA's older adult fasting glucose recommendations. [5]

HealthRX Geriatric Tresiba Titration Framework:

| Fasting Glucose (mg/dL) | Action | |---|---| | <70 | Reduce dose by 4 units; contact clinician same day | | 70 to 130 | No change | | 131 to 160 | Increase by 2 units in 3 days | | 161 to 200 | Increase by 2 to 4 units in 3 days | | >200 | Increase by 4 units; recheck in 3 days; consider same-day contact |

Step 4: Monitoring During the First 30 Days

Daily fasting glucose logs for the first two weeks are the minimum standard. Patients or caregivers should also check a pre-bedtime glucose reading, because degludec's long half-life means a dose that is too high will produce a trough 12 to 18 hours after injection, often in the early morning hours. A pre-bed glucose below 120 mg/dL in a geriatric patient on degludec warrants a bedtime snack or dose review.

Recheck HbA1c at 3 months after the transition. Recheck renal function (eGFR, potassium) at 4 weeks if eGFR was borderline at baseline.

Hypoglycemia Risk Management in the 65+ Population

Hypoglycemia is the single most dangerous short-term complication of basal insulin therapy in older adults. It accounts for more emergency department visits in this age group than hyperglycemia. [10]

Why Older Adults Are More Vulnerable

Three physiologic changes compound hypoglycemia risk after age 65:

1. Blunted glucagon response. The counter-regulatory glucagon surge that rescues blood glucose during hypoglycemia weakens with age and with longer diabetes duration. [11]
2. Reduced adrenergic symptoms. Many older adults on beta-blockers or with autonomic neuropathy lose tremor, palpitations, and sweating as early warning signs, leaving confusion or unconsciousness as the first detectable symptom.
3. Slower gastric emptying. Delayed gastric motility (common in long-standing diabetes) delays carbohydrate absorption, making the standard "15 grams of fast carbohydrate" rescue protocol less reliable.

Practical Safeguards

• Prescribe glucagon (nasal glucagon 3 mg or glucagon kit 1 mg IM) at the same time as Tresiba for any geriatric patient living alone or with a caregiver who cannot administer oral glucose reliably.
• Counsel caregivers on the "15-15 rule" modified for this population: give 20 grams of fast-acting carbohydrate, recheck in 15 minutes, repeat if glucose is still below 70 mg/dL.
• Set a glucose alert on any continuous glucose monitor (CGM) at 80 mg/dL in geriatric patients, not 70 mg/dL, to allow a wider safety margin.
• Consider CGM for any older adult on basal insulin who has had one or more hypoglycemic events in the prior 12 months. The ADA 2024 Standards support CGM use in older adults on insulin. [5]

Renal and Hepatic Considerations

Tresiba does not have dose adjustment recommendations in the FDA label specifically for hepatic impairment or renal impairment, but the label explicitly warns that both conditions may alter insulin requirements and increase hypoglycemia risk. [9]

Renal Impairment

A pharmacokinetic study of degludec in subjects with varying renal function (including end-stage renal disease) found no clinically relevant difference in degludec exposure across renal function groups. [12] However, patients with eGFR <30 mL/min/1.73 m2 clear glucose more slowly and have reduced renal gluconeogenesis, both of which lower the glucose threshold at which hypoglycemia becomes dangerous. In these patients, consider reducing the target fasting glucose range to 100 to 150 mg/dL and monitoring more frequently.

Hepatic Impairment

Insulin requirements may decrease with hepatic impairment because the liver is a primary site of insulin degradation. No formal degludec pharmacokinetic study in hepatic impairment has been published, but clinical consensus supports starting at or below 80% of the prior basal dose and titrating cautiously.

Device Considerations: FlexTouch Pen in Older Adults

The Tresiba FlexTouch pen requires no priming and has a low injection force, a feature that matters for patients with arthritis or reduced hand strength. A 2017 human factors study found that the FlexTouch pen required significantly less injection force than the SoloSTAR pen (used for glargine), which may reduce dose errors in patients with limited dexterity. [13]

U-100 vs. U-200

Tresiba is available as both U-100 (each unit = 0.01 mL) and U-200 (each unit = 0.005 mL). At doses above 200 units per day, the U-200 pen reduces injection volume. For most geriatric patients requiring 10 to 80 units per day, U-100 is standard. The U-200 pen doses in units (not mL), so conversion errors are avoided by design, but caregivers should still be counseled that U-200 vials do not exist and the pen must not be used with syringes.

Syringe Caution

Never draw degludec from the FlexTouch pen into a syringe. The pen cartridge is not designed for needle penetration outside of the pen mechanism, and dose accuracy cannot be guaranteed by this method. For patients requiring syringe-based administration due to severe arthritis or other device barriers, a clinician should contact Novo Nordisk for alternative access solutions.

Comparing Degludec to Other Basal Insulins in Older Adults

The choice of basal insulin in a geriatric patient is not always straightforward. Three options dominate clinical practice: glargine U-100, glargine U-300, and degludec U-100.

Degludec vs. Glargine U-100

The SWITCH 2 trial (N=721, type 2 diabetes, crossover design) compared degludec and glargine U-100 in patients at risk for hypoglycemia. Degludec produced 30% fewer overall symptomatic hypoglycemic episodes (rate ratio 0.70, 95% CI 0.61 to 0.80, P<0.001) and 42% fewer nocturnal symptomatic episodes (rate ratio 0.58, 95% CI 0.45 to 0.74, P<0.001) with similar HbA1c outcomes. [14] While SWITCH 2 was not exclusively a geriatric trial, its "at-risk" inclusion criteria (prior hypoglycemia, renal impairment, older age) make its population highly representative of the patients described in this article.

Degludec vs. Glargine U-300

Head-to-head data between degludec and glargine U-300 in geriatric patients specifically is limited. The BRIGHT trial (N=929) compared them in a broader type 2 population and found similar overall hypoglycemia rates, though glargine U-300 showed a slight advantage during the titration phase while degludec showed a slight advantage during the maintenance phase. [15] Neither drug is clearly superior for all geriatric patients; the practical decision often hinges on formulary access, prior authorization, and pen device compatibility.

When to Choose Degludec

Degludec is a strong choice for older adults who:

• Have had nocturnal hypoglycemia on glargine U-100
• Require dosing flexibility due to variable schedules or caregiver availability
• Have dexterity limitations that benefit from the low-force FlexTouch pen
• Are transitioning from a twice-daily NPH regimen and need simplification to once-daily dosing

Cognitive and Social Determinants Specific to Geriatric Transitions

A transition to adult care for geriatric patients often coincides with a change in clinical setting: from a pediatric or young-adult endocrinologist to a general internist, geriatrician, or primary care provider who may have less diabetes subspecialty experience.

The ADA 2024 Standards note that insulin-related errors are more common in older adults during care transitions, and they recommend structured handoff protocols that include a medication reconciliation step specifically for insulin. [5] At minimum, the receiving clinician should document the exact prior dose, pen device, and injection site before writing a new Tresiba prescription.

Cognitive screening using a validated tool such as the Mini-Cog (3-item recall plus clock drawing) takes under three minutes and can identify patients who may not be able to self-manage basal insulin titration reliably. Patients who score below the Mini-Cog cutoff should have a designated caregiver assigned to insulin administration and glucose logging before discharge or transition.

Social isolation is an independent risk factor for insulin-related adverse events in older adults. Patients living alone should receive a structured check-in plan, either from a home health aide, a telehealth nurse, or a family member, for at least the first 30 days after any basal insulin transition.

Deprescribing Considerations

Not every geriatric patient needs to remain on basal insulin. For patients aged 80 and older, with multiple comorbidities, HbA1c at or below the target range, and declining appetite or weight, a clinician-supervised insulin dose reduction or discontinuation may be appropriate.

The ADA's 2024 guidance supports considering insulin deprescribing when the risks of hypoglycemia outweigh the benefits of tight glycemic control, particularly in patients with life expectancy under five years or severe functional decline. [5] Degludec's long half-life means that dose reductions take 2 to 3 days to produce their full effect, so deprescribing should follow the same stepwise approach as dose titration: reduce by 10 to 20% every 3 to 4 days, monitoring fasting glucose throughout.